SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Generic Medicines: Solutions for a Sustainable Drug Market?
16 references·0 citing·46 second hop
Generic Medicines: Solutions for a Sustainable Drug Market? (2013)Generic Medicines: Solutions for a Sustai…Demand-side policies to encourage the use of generic medicines: an overview (2013)Demand-side policies to encou…The impact of pharmaceutical pricing and reimbursement policies on generics uptake: implementation of policy options on generics in 29 European countries─an overview (2012)The impact of pharmaceutical …Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications (2012)Ongoing measures to enhance t…A decade of change (2012)A decade of changeThe ‘Wise List’– A Comprehensive Concept to Select, Communicate and Achieve Adherence to Recommendations of Essential Drugs in Ambulatory Care in Stockholm (2011)The ‘Wise List’– A Comprehens…Policies to Enhance Prescribing Efficiency in Europe: Findings and Future Implications (2011)Policies to Enhance Prescribi…Differences in external price referencing in Europe—A descriptive overview (2011)Differences in external price…Use of Generics—A Critical Cost Containment Measure for All Healthcare Professionals in Europe? (2010)Use of Generics—A Critical Co…Ongoing pharmaceutical reforms in France (2010)Ongoing pharmaceutical reform…Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance (2009)Multifaceted national and reg…Recent National and Regional Drug Reforms in Sweden (2008)Recent National and Regional …Clinical Equivalence of Generic and Brand-Name Drugs Used in Cardiovascular Disease (2008)Clinical Equivalence of Gener…International comparison of generic medicine prices (2007)International comparison of g…Sustaining Generic Medicines Markets in Europe (2006)Sustaining Generic Medicines …The pharmaceutical industry as a medicines provider (2002)The pharmaceutical industry a…Moral hazard in physician prescription behavior (2000)Moral hazard in physician pre…Statistical Methods for Meta-Analysis (1988)Assessing the quality of reports of randomized clinical trials: Is blinding necessary? (1996)Evaluating non-randomised intervention studies (2003)Comparing Generic and Innovator Drugs: A Review of 12 Years of Bioequivalence Data from the United States Food and Drug Administration (2009)A review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generic medicines, using Ireland as a case study (2013)Comparing Generic Drug Markets in Europe and the United States: Prices, Volumes, and Spending (2017)A Computationally Efficient Quadrature Procedure for the One-Factor Multinomial Probit Model (1982)The economics of moral hazard: comment (1982)Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act (1992)Pharmaceutical reform and physician strikes in Korea: separation of drug prescribing and dispensing (2003)Financial incentives and physicians’ prescription decisions on the choice between brand-name and generic drugs: Evidence from Taiwan (2008)Physician Agency and Adoption of Generic Pharmaceuticals (2012)Cross-national price differences for pharmaceuticals: how large, and why? (2000)The impact of price regulation on the launch delay of new drugs—evidence from twenty‐five major markets in the 1990s (2004)Pharmaceutical Price Controls and Entry Strategies (2007)Value in Pharmaceutical Pricing (2013)Policy options for pharmaceutical pricing and purchasing: issues for low- and middle-income countries (2014)The Swedish Council on Technology Assessment in Health Care (1989)Health systems in transition. (2010)Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? (2014)Diffusion of Innovations 1 (2019)Review of the literature on reference pricing (2000)Encouraging the use of generic medicines: implications for transition economies. (2002)Competition in off-patent drug markets: Issues, regulation and evidence (2008)The experiences of implementing generic medicine policy in eight countries: A review and recommendations for a successful promotion of generic medicine use (2013)Cost of innovation in the pharmaceutical industry (1991)Success rates for new drugs entering clinical testing in the United States (1995)Access to Essential Drugs in Poor Countries (1999)Prices & availability of common medicines at six sites in India using a standard methodology. (2007)The Effect Of Regulation On Pharmaceutical Revenues: Experience In Nineteen Countries (2008)Does the Market Share of Generic Medicines Influence the Price Level? (2011)Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies (2006)THE WORLD MEDICINES SITUATION 2011 (2011)Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries (2013)Definition and Classification of Generic Drugs Across the World (2015)European Healthcare Policies for Controlling Drug Expenditure (2003)Patients’ attitudes towards and experiences of generic drug substitution in Norway (2006)Patients’ Perceptions Of Generic Medications (2009)Fixed dose drug combinations – are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries (2020)Institutionalized Organizations: Formal Structure as Myth and Ceremony (1977)The Audit Society: Rituals of Verification (1999)Ongoing Initiatives to Improve the Quality and Efficiency of Medicine Use within the Public Healthcare System in South Africa; A Preliminary Study (2017)Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets (2018)Big Pharma, little science? (2012)priority Medicines for Europe and the World: 2013 update (2013)Review symposium on There Goes the Gayborhood? (2015)
this work references cited by second hop

References

  • 2008Clinical Equivalence of Generic and Brand-Name Drugs Used in Cardiovascular Disease432 cited
  • 2011The ‘Wise List’– A Comprehensive Concept to Select, Communicate and Achieve Adherence to Recommendations of Essential Drugs in Ambulatory Care in Stockholm224 cited
  • 2002The pharmaceutical industry as a medicines provider165 cited
  • 2000Moral hazard in physician prescription behavior164 cited
  • 2006Sustaining Generic Medicines Markets in Europe161 cited
  • 2009Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance150 cited
  • 2012A decade of change140 cited
  • 2011Differences in external price referencing in Europe—A descriptive overview132 cited
  • 2012The impact of pharmaceutical pricing and reimbursement policies on generics uptake: implementation of policy options on generics in 29 European countries─an overview115 cited
  • 2011Policies to Enhance Prescribing Efficiency in Europe: Findings and Future Implications113 cited
  • 2010Ongoing pharmaceutical reforms in France108 cited
  • 2012Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications97 cited
  • 2010Use of Generics—A Critical Cost Containment Measure for All Healthcare Professionals in Europe?93 cited
  • 2013

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

Demand-side policies to encourage the use of generic medicines: an overview
87 cited
  • 2007International comparison of generic medicine prices86 cited
  • 2008Recent National and Regional Drug Reforms in Sweden85 cited
  • Cited by

    No citing works inside the corpus for this window.